PA-BOOMI
9.5.2024 15:01:33 CEST | Business Wire | Press release
Boomi™, the intelligent integration and automation leader, today announced an enhanced version of Boomi for SAP to help accelerate the migration of SAP Business Warehouse (SAP BW) customers to SAP Datasphere. By leveraging Amazon Web Services (AWS), Boomi aims to address the critical challenge of enterprise customers who need to transition to SAP Datasphere, and unlock the full potential of their business data in a cost-effective and streamlined way.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240509748233/en/
Boomi to Simplify and Accelerate the Move to SAP Datasphere (Graphic: Business Wire)
Addressing a Critical Challenge in Data Migration
With mainstream support ending for SAP BW coming at the close of 2027, SAP BW customers are encouraged to migrate to SAP Datasphere, which will enable business transformation by delivering seamless, scalable access to business-critical data. However, the move to SAP Datasphere requires significant investment and substantial effort from highly-skilled individuals.
Boomi for SAP accelerates the transition to SAP Datasphere on AWS through Boomi’s low-code, integration platform. Customers can simply log into the Boomi Enterprise Platform and leverage a pre-built accelerator specifically designed to speed the migration and integration of data into SAP Datasphere on AWS.
“SAP Datasphere is SAP's foundation for a business data fabric, but many companies with earlier versions of SAP BW are overburdened with the cost-prohibitive, time-consuming, and resource-intensive process of migrating to it,” said Steve Lucas, CEO at Boomi. “This new collaboration leverages Boomi’s expertise in intelligent integration and automation, along with AWS services, to provide a lighter, faster, more cost-effective way for organizations to transition to SAP Datasphere, getting the most out of their SAP investments and their data.”
Key benefits of Boomi for SAP include:
- Avoid costly SAP BW version upgrades and the need for a staging area, resulting in time and cost savings
- The ability to select which SAP BW Queries and BW InfoProviders to move to Datasphere
- Efficient data tiering to SAP Datasphere and Amazon Redshift, a fully managed, petabyte-scale data warehouse service, enabling businesses to move less frequently used data to more affordable cloud storage tiers
- Faster integration of third-party data into SAP Datasphere at a lower cost
- Better data preparation for more efficient use of data analytics and artificial intelligence (AI)
- A smooth procurement process in AWS Marketplace, a digital catalog with thousands of software listings from independent software vendors that make it easy to find, test, buy, and deploy software that runs on AWS
“The ability to aggregate diverse datasets is emerging as a critical advantage as organizations recognize the pivotal role of AI in their operations,” said Matt Aslett, director of research at Ventana Research, part of ISG. “Data preparation and integration is imperative to ensuring more efficient utilization of data analytics and AI, and the acceleration of business outcomes through data-driven decision-making.”
“Working with AWS reinforces Boomi’s commitment to delivering a practical path to enterprise analytics and AI, beginning with a robust data foundation,” said Ed Macosky, Chief Product and Technology Officer at Boomi. “With the Boomi Enterprise Platform, organizations can achieve a more flexible, scalable, and connected ecosystem to drive innovation, future-proof their IT investments, reduce total cost of ownership, and enhance business outcomes.”
Availability
Boomi for SAP is available in AWS Marketplace, and on the Boomi Enterprise Platform.
Additional Resources
- Find Boomi in AWS Marketplace
- Explore Boomi Recipes and Accelerators for SAP in the Discover Catalog
- Explore the Boomiverse Community
- Follow Boomi on X (Twitter), LinkedIn, Facebook, and YouTube
About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509748233/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com
Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press release
Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that
2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press release
CEO of Zhong, one of YouTube’s most-watched creators with 70 million subscribers and 95 million followers on all platforms, joins program The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release
A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom